Keywords: Taihua, paclitaxel, APIs, China, Europe
“Higher margin” European anti-cancer sales targeted for 2010 by China’s Taihua
Article | 30 September 2009
The AIM-quoted Chinese pharmaceutical manufacturer Taihua has disclosed initial details of plans for high-margin European sales of the active pharmaceutical ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
